ITCI Company Profile and Key Details

Q: Who are the executives of ITCI?

Dr. Robert E. Davis Ph.D.Senior Vice President & Chief Scientific OfficerMs. Karen Patruno Sheehy Esq.Senior Vice President & Chief Compliance OfficerDr. Michael OlchaskeySenior Vice President & Head of Regulatory AffairsMr. Mark NeumannEVice President & Chief Commercial OfficerMr. Juan Fernando SanchezVice President of Corporation Communications & Investor RelationsMr. Lawrence J. Hineline CPA, CPASenior Vice President of Fin., Chief Financial Officer, Treasurer & Assistant Sec.Mr. John A. BardiSenior Vice President of Market Access, Policy & Gov. AffairsDr. Sharon Mates Ph.D.Co-Founder, Chairman, Chief Executive Officer & PresMr. Michael I. Halstead J.D.Executive Vice President, Gen. Counsel & Sec.Dr. Suresh K. Durgam M.D.Executive Vice President & Chief Medical Officer

NASDAQ : ITCI

Intra-Cellular Therapies

$131.87

At Close 4:00 PM

Not Actively Trading

67.83

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Intra-Cellular Therapies, Inc. (ITCI) stock remained unchanged at $131.87 a share on NASDAQ. The stock opened at $131.87, fluctuating between $131.87 to $131.87 during the session.

Stock Snapshot

131.87

Prev. Close

14.05B

Market Cap

131.87

Day Low

-180.64383561643837

P/E Ratio

-0.73

EPS (TTM)

-1.29

Cash Flow per Share

131.87

Open

106.52M

Number of Shares

131.87

Day High

98.4%

Free Float in %

6.14

Book Value

16.04M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 01, 2025	131.90	131.98	131.63	131.87	15.53M
Mar 31, 2025	131.84	131.95	131.80	131.92	2.55M
Mar 28, 2025	131.85	131.87	131.79	131.81	1.58M
Mar 27, 2025	131.75	131.79	131.71	131.75	1.87M
Mar 26, 2025	131.78	131.78	131.65	131.69	1.02M
Mar 25, 2025	131.75	131.79	131.63	131.70	1.13M
Mar 24, 2025	131.58	131.71	131.58	131.70	661.02K
Mar 21, 2025	131.55	131.67	131.51	131.65	1.84M
Mar 20, 2025	131.55	131.60	131.50	131.60	921.9K
Mar 19, 2025	131.45	131.57	131.45	131.53	1.23M
Mar 18, 2025	131.42	131.48	131.35	131.45	1.47M
Mar 17, 2025	131.29	131.46	131.27	131.45	996.8K
Mar 14, 2025	131.28	131.40	131.24	131.26	1.5M
Mar 13, 2025	131.24	131.37	131.22	131.36	1.8M
Mar 12, 2025	131.25	131.33	131.19	131.25	2.68M
Mar 11, 2025	131.24	131.37	131.23	131.24	3.74M
Mar 10, 2025	131.21	131.28	131.20	131.25	2.62M
Mar 07, 2025	131.30	131.32	131.21	131.24	1.26M
Mar 06, 2025	131.23	131.28	131.20	131.25	1.16M
Mar 05, 2025	131.28	131.35	131.18	131.19	2.87M

Contact Details

New York City, NY 10016

United States

https://www.intracellulartherapies.com 646 440 9333

About Company

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which is in Phase III clinical trial for the treatment of bipolar depression, as well as to treat autism spectrum disorder; and in additional neuropsychiatric indications, such as sleep disorders associated with neuropsychiatric and neurological disorders. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease and heart failure; ITI-1284-ODT-SL for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression and anxiety. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Stock Peers

NBIX

3.27+2.37%

Neurocrine Biosciences, Inc.$141.20 ANIP

0.34+0.42%

ANI Pharmaceuticals, Inc.$81.84 LNTH

0.03+0.05%

Lantheus Holdings, Inc.$64.89 PAHC

3.07+6.14%

Phibro Animal Health Corporation$53.07 SUPN

2.28+4.62%

Supernus Pharmaceuticals, Inc.$51.65 COLL

0.69+1.47%

Collegium Pharmaceutical, Inc.$47.61 HROW

1.26+2.74%

Harrow Health, Inc.$47.32 INDV

-0.09-0.26%

Indivior Pharmaceuticals Inc$34.36 PETQ

-0.01-0.03%

PetIQ, Inc.$30.98 AMPH

0.63+2.20%

Amphastar Pharmaceuticals, Inc.$29.26

Company Overview

The stock is currently trading near its 52-week high $64.09 and $131.98. With a market capitalization of about $14.05 billion, Intra-Cellular Therapies, Inc. is classified as a large-cap and shows lower-than-market volatility (beta ~0.46). Key stats such as the average daily volume over the past year has been around 3.62 million shares, trading with heavier-than-usual volume. Headquartered in New York City, NY, Intra-Cellular Therapies, Inc. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Sharon Mates, the company employs approximately 860 people and listed since January 07, 2014. Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 0.28%, SMA50 1.98%, SMA200 42.8%). The stock’s 14-day RSI is 84.55 (overbought), while the ATR of 0.35 points to tighter daily ranges. The stock remains sitting in the mid-range of its 52-week band, trading -0.08% below its high and over 105.76% above its low.

Valuation Metrics

Intra-Cellular Therapies, Inc. trades at a P/E ratio of -314.75, slightly below the S&P 500 average, with a price-to-sales ratio of 37.52 and a price-to-book ratio of 11.84 reflecting a rich premium to book value. The P/FCF stands at -352.3, also below market averages. Compared to sector medians, Intra-Cellular Therapies, Inc. P/S is trading rich, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Intra-Cellular Therapies, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.61. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Intra-Cellular Therapies, Inc. generated EPS of -$0.72 over the past year. Five-year average earnings growth is 23.01%. The latest quarter delivered EPS of -$0.16. The next quarter is forecast at -$0.08. Next year's EPS is expected at $66.36. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $132.00 to $132.00. The high target offers 0.1% upside. The low target suggests 0.1% downside. The mean target is $132.00. This offers 0.1% upside. Intra-Cellular Therapies, Inc. earnings surprise history is a mixed track record. The quarter that ended February 21, 2025, missed forecasts by 100.0%. The prior quarter beat by 24.44%. Over the last six quarters, Apple has recorded several small beats. These include -31.82% in January 09, 2024.

Shareholding & Insider Activity

Intra-Cellular Therapies, Inc. has 106.33 million shares outstanding. The public float is 104.08 million shares, elevated short interest at 2.22% of float. This equals 2.33 million shares. The short ratio is 1.19 days. Institutional investors hold 98.91% of the float. Insiders own 2.48%. Mates Sharon holds 1.07 million shares, RIGGS RORY B has 116.60 thousand shares and MARCUS JOEL S has 39.66 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Intra-Cellular Therapies generated $462.18M in revenue, or $4.82 per share. Gross margin was 92.70%, operating margin -34.48%, and net profit margin -30.22%. Returns are negative, with ROA at -19.18% and ROE at -23.62%.
On valuation metrics, Intra-Cellular Therapies trades at a P/E of -314.75, P/S of 37.52 and P/B of 11.84. The current ratio is 6.36 and quick ratio is 6.23. Operationally, the company’s inventory turnover is 1.36 and cash conversion cycle is 164.46 days. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -2.33.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Intra-Cellular Therapies posted revenue of $462.18M, down slightly from $249.13M in the prior quarter. Gross profit was $428.43M (margin 92.70%). Operating income was - $159.38M (margin -34.5%). Net income was- $139.67M (EPS - $1.46).
The company ended the quarter with $497.94M in cash and short-term investments, a total debt of $16.94M, and net debt of - $130.83M. Total assets were $728.30M, with equity of $591.42M. Financials further reflected weakness, with operating cash flow of - $124.20M, free cash flow of - $124.47M, and capital expenditures of - $269.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Intra-Cellular Therapies, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.26%, with price expected at $132.21 by April 15, 2025, within a range of $123.00 to $141.33 3-Month Outlook: Projected rise of 130.13%, reaching $303.47 by June 30, 2025, with a range of $302.31 to $304.63. 1-Year Outlook: Projected gain of 11.81%, with price at $147.44 by April 01, 2026, within a range of $142.35 to $151.59.

Key Takeaways

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shares are up 57.89% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Intra-Cellular Therapies, Inc. trading at a premium to the broader market with a P/E of -314.75. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $82.04, suggesting -37.79% downside. Our AI forecast model points to short-term strength (0.26% over two weeks), a medium-term rise (130.13% over three months), and a longer-term gain (11.81% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Intra-Cellular Therapies, Inc. (ITCI) stock price?

Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) stock price is $131.87 in the last trading session. During the trading session, ITCI stock reached the peak price of $131.87 while $131.87 was the lowest point it dropped to. The percentage change in ITCI stock occurred in the recent session was 0% while the dollar amount for the price change in ITCI stock was $0.00.

ITCI's industry and sector of operation?

The NASDAQ listed ITCI is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Intra-Cellular Therapies, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ITCI?

Dr. Robert E. Davis Ph.D.
Senior Vice President & Chief Scientific Officer
Ms. Karen Patruno Sheehy Esq.
Senior Vice President & Chief Compliance Officer
Dr. Michael Olchaskey
Senior Vice President & Head of Regulatory Affairs
Mr. Mark Neumann
EVice President & Chief Commercial Officer
Mr. Juan Fernando Sanchez
Vice President of Corporation Communications & Investor Relations
Mr. Lawrence J. Hineline CPA, CPA
Senior Vice President of Fin., Chief Financial Officer, Treasurer & Assistant Sec.
Mr. John A. Bardi
Senior Vice President of Market Access, Policy & Gov. Affairs
Dr. Sharon Mates Ph.D.
Co-Founder, Chairman, Chief Executive Officer & Pres
Mr. Michael I. Halstead J.D.
Executive Vice President, Gen. Counsel & Sec.
Dr. Suresh K. Durgam M.D.
Executive Vice President & Chief Medical Officer

How ITCI did perform over past 52-week?

ITCI's closing price is 105.76% higher than its 52-week low of $64.09 where as its distance from 52-week high of $131.98 is -0.08%.

How many employees does ITCI have?

Number of ITCI employees currently stands at 860.

Link for ITCI official website?

Official Website of ITCI is: https://www.intracellulartherapies.com

How do I contact ITCI?

ITCI could be contacted at phone 646 440 9333 and can also be accessed through its website. ITCI operates from 430 East 29th Street, New York City, NY 10016, United States.

How many shares of ITCI are traded daily?

ITCI stock volume for the day was 16.04M shares. The average number of ITCI shares traded daily for last 3 months was 3.62M.

What is the market cap of ITCI currently?

The market value of ITCI currently stands at $14.05B with its latest stock price at $131.87 and 106.52M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	860
Beta	0.46
Sales or Revenue	$462.18M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

ITCI Company Profile and Key Details

Intra-Cellular Therapies

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Earnings & Analyst Outlook

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Valuation Metrics

Key Takeaways

Price Forecast & Outlook